ESPE2024 Poster Category 2 Late Breaking (107 abstracts)
Real-world IGF-1 Variations & Its Management in Children on Recombinant Human Growth Hormone (rhGH) Therapy (RIGHT Study)
Suet Ching Chen 1,2 , Malika Alimussina 1,2 , Sanhita Koley 1,2 , Sheila Shepherd 1 , Abdulmoein Eid Al-Agha 3 , Nadia Amin 4 , Navoda Atapattu 5 , JiaJia Chen 6 , Yana Deyanova 7 , Antony Fu 8 , Michael Højby 9 , Alexander Augusto de Lima Jorge 10 , Violeta Iotova 7 , Dominika Januś 11 , Renata Markosyan 12 , Bradley S. Miller 13 , Lars Savendahl 14 , Sumudu Nimali Seneviratne 15 , M Guftar Shaikh 1 , Savitha Shenoy 16 , Lloyd J W Tack 17 , Malgorzata Wasniewska 18 & S Faisal Ahmed 1,2
1Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, United Kingdom. 2Office for Rare Conditions Registries, University of Glasgow, Glasgow, United Kingdom. 3King Abdulaziz University Hospital, Jeddah, Saudi Arabia. 4Leeds Children’s Hospital, Leeds, United Kingdom. 5Lady Ridgeway Hospital for Children, Colombo, Sri Lanka. 6Beijing Children’s Hospita, Beijing, China. 7Medical University UMHAT “Sv. Marina”, Varna, Bulgaria. 8Princess Margaret Hospital, Hong Kong, China. 9Novo Nordisk, Denmark, Netherlands. 10Endocrinology Division of Hospital das Clinicas of University of Sao Paulo School of Medicine, Sao Paolo, Brazil. 11Jagiellonian University and University Children Hospital, Krakow, Poland. 12Yerevan State Medical University, Wigmore Women & Children’s Hospital, Yerevan, Armenia. 13M Health Fairview Masonic Children’s Hospital, University of Minnesota, Minnesota, USA. 14Karolinska Institutet, Stockholm, Sweden. 15University of Colombo, Colombo, Sri Lanka. 16Leicester Children’s Hospital, Leicester, United Kingdom. 17Ghent University Hospital, Ghent, Belgium. 18Department of Human Pathology of Adulthood and Childhood University of Messina, Messina, Italy
Aim: Serum IGF-1 is widely advocated as a tool for monitoring adherence, safety and effectiveness of recombinant human growth hormone (rhGH). However, there is a need to understand the real-world variations in IGF-1 levels in children on rhGH and the management of abnormal IGF-1 levels in routine clinical practice.
Method: Centres participating in the Global Registry for Novel Therapies in Rare Bone and Endocrine Conditions (www.GloBE-Reg.net) were invited to complete the minimum dataset for rhGH therapy. Information on the indications for rhGH therapy, gender, age at diagnosis and rhGH initiation, rhGH doses and serum IGF-1 on therapy were collected for analysis. Results are shown in median (range).
Results: Since study launch in Jan 2024, 1,716 IGF-1 values from 262 cases were available from 14 centres in 10 countries. For a subset of 351 IGF-1 values from 79 cases (54M: 25F) in 2 centres, reference data were available for analysis. The main indications for rhGH treatment in these 79 cases included GHD in 43 (54%), Prader Willi syndrome (PWS) in 11 (14%), small for gestational age (SGA) in 11 (14%) with a few other indications. All the patients were on daily rhGH, except one on LAGH. Seventy-five (21%) of the IGF-1 values were 2 standard deviations (SD) outside the mean for age and sex (SDS). Of the 75, the IGF-1 values were below –2SDS in 28 (37%) [median, –2.68 (range, -3.9, -2.25)] and above +2SDS in 47 (63%) [median, +2.62 (+2.08, +4.49)]. The rhGH doses for the group with low and high IGF-1 values were 29 (17,43) and 27 (11,44) mcg/kg/day. Children with PWS (P <0.001) and SGA (P <0.02) were more likely to have high IGF-1 levels compared to GHD. Data on clinical management were available for 23/28 (82%) low IGF-1 values. In 14 (61%), a dose increment of 17% (7,100) was recorded; no dose change was recorded on 9 occasions. Adherence information was only available in 2/28 (7%) of the low IGF-1 values. Of the 47 high results, 8 (17%) had dose reduction by 15% (4,47), with no change in 23 (49%) and a further dose increase by 15% (7,50) in 16 (34%).
Conclusions: A fifth of serum IGF-1 values in children on rhGH treatment are outside the assay reference range and this is more likely in those with SGA and PWS. Further studies are required to better understand the value of measuring serum IGF-1 in routine clinical practice.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more